Autopsy report · NCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

“Due to operational and regulatory considerations.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 1 year 5 months before it stopped.
• 68 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Aardvark Therapeutics, Inc.

Sponsor type

Industry

Conditions

Hyperphagia; Prader-Willi Syndrome

Interventions

Placebo; ARD-101

Participants

68

Sites

31

Countries

Australia, Canada, South Korea, United Kingdom, United States

Trials that died the same way

• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (71% match in meaning)
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
  “Due to a lack of safety and efficacy.” (68% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (68% match in meaning)
• Pilot Study Evaluating Stress Response and Immune Function in Mechanically Ventilated Patients With Alcohol Use Disorders Treated With Propofol or Midazolam
  “Due to logistical purposes” (66% match in meaning)
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.